fbpixel

Stroke research studies for holistic treatments

Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after stroke treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of stroke and related therapies
as they heal people who benefited from our expertise.

/ title=”Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular and stroke.”>
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular and stroke.

June 2004

Background:
Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) are widely used for the treatment of hypercholesterolemia and coronary heart and for the prevention of stroke. There have been various adverse effects, most commonly affecting muscle and ranging from myalgia to rhabdomyolysis. These adverse effects may be due to a coenzyme Q(10) (CoQ(10)) deficiency because inhibition of cholesterol biosynthesis also inhibits the synthesis of CoQ(10). OBJECTIVE:
To measure CoQ(10) levels in blood from hypercholesterolemic subjects before and after exposure to atorvastatin calcium, 80 mg/d, for 14 and 30 days.
DESIGN:
Prospective blinded study of the effects of short-term exposure to atorvastatin on blood levels of CoQ(10).
SETTING:
Stroke center at an academic tertiary care hospital. Patients We examined a cohort of 34 subjects eligible for statin treatment according to National Cholesterol Education Program: Adult Treatment Panel III criteria.
Results:
The mean +/- SD blood concentration of CoQ(10) was 1.26 +/- 0.47 micro g/mL at baseline, and decreased to 0.62 +/- 0.39 micro g/mL after 30 days of atorvastatin therapy (P

/ onclick=”MoreLine(‘9282’, ‘Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular and stroke.’)”>
…more

/ title=”Association between the current use of low-dose oral contraceptives and cardiovascular arterial : a meta-analysis.”>
Association between the current use of low-dose oral contraceptives and cardiovascular arterial : a meta-analysis.

July 2005

CONTEXT: The long-term cardiovascular safety of widely used oral contraceptives (OCs) is still debated, and no meta-analysis assesses the modern use of OCs and the associated cardiovascular risks. OBJECTIVE:
We aimed to assess the risk of cardiovascular s associated with current use of low-dose combined OCs. DATA SOURCES: All studies published between January 1980 and October 2002 were searched using MEDLINE, BIOSIS, and Scientific Citations. STUDY SELECTION: Original studies were selected independently by two investigators (J.P.B., P.A.E.) based on inclusion criteria: low-dose combined OC (

/ onclick=”MoreLine(‘9280’, ‘Association between the current use of low-dose oral contraceptives and cardiovascular arterial : a meta-analysis.’)”>
…more

/ title=”Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.”>
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

July 2010

CONTEXT: Studies have suggested that the use of rosiglitazone may be associated with an increased risk of serious cardiovascular events compared with other treatments for type 2 diabetes. OBJECTIVE:
To determine if the risk of serious cardiovascular harm is increased by rosiglitazone compared with pioglitazone, the other thiazolidinedione marketed in the United States. DESIGN, SETTING, AND PATIENTS: Nationwide, observational, retrospective, inception cohort of 227,571 Medicare beneficiaries aged 65 years or older (mean age, 74.4 years) who initiated treatment with rosiglitazone or pioglitazone through a Medicare Part D prescription drug plan from July 2006-June 2009 and who underwent follow-up for up to 3 years after thiazolidinedione initiation. MAIN OUTCOME MEASURES: Individual end points of acute myocardial infarction (AMI), stroke, heart failure, and all-cause mortality (death), and composite end point of AMI, stroke, heart failure, or death, assessed using incidence rates by thiazolidinedione, attributable risk, number needed to harm, Kaplan-Meier plots of time to event, and Cox proportional hazard ratios for time to event, adjusted for potential confounding factors, with pioglitazone as reference.
Results:
A total of 8667 end points were observed during the study period. The adjusted hazard ratio for rosiglitazone compared with pioglitazone was 1.06 (95% confidence interval [CI], 0.96-1.18) for AMI; 1.27 (95% CI, 1.12-1.45) for stroke; 1.25 (95% CI, 1.16-1.34) for heart failure; 1.14 (95% CI, 1.05-1.24) for death; and 1.18 (95% CI, 1.12-1.23) for the composite of AMI, stroke, heart failure, or death. The attributable risk for this composite end point was 1.68 (95% CI, 1.27-2.08) excess events per 100 person-years of treatment with rosiglitazone compared with pioglitazone. The corresponding number needed to harm was 60 (95% CI, 48-79) treated for 1 year.
Conclusion:
Compared with prescription of pioglitazone, prescription of rosiglitazone was associated with an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older.

/ onclick=”MoreLine(‘9267’, ‘Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.’)”>
…more

/ title=”Folic Acid Supplementation and the Risk of Cardiovascular s: A Meta-Analysis of Randomized Controlled Trials.”>
Folic Acid Supplementation and the Risk of Cardiovascular s: A Meta-Analysis of Randomized Controlled Trials.

August 2016

Background:
Results from observational and genetic epidemiological studies suggest that lower serum homocysteine levels are associated with lower incidence of cardiovascular (CVD). Numerous randomized controlled trials have investigated the efficacy of lowering homocysteine with folic acid supplementation for CVD risk, but conflicting results have been reported. METHODS AND
Results:
Three bibliographic databases (Medline, Embase, and the Cochrane Database of Systematic Reviews) were searched from database inception until December 1, 2015. Of the 1933 references reviewed for eligibility, 30 randomized controlled trials involving 82 334 participants were included in the final analysis. The pooled relative risks of folic acid supplementation compared with controls were 0.90 (95% CI 0.84-0.96; P=0.002) for stroke, 1.04 (95% CI 0.99-1.09; P=0.16) for coronary heart , and 0.96 (95% CI 0.92-0.99; P=0.02) for overall CVD. The intervention effects for both stroke and combined CVD were more pronounced among participants with lower plasma folate levels at baseline (both P

/ onclick=”MoreLine(‘9238’, ‘Folic Acid Supplementation and the Risk of Cardiovascular s: A Meta-Analysis of Randomized Controlled Trials.’)”>
…more

/ title=”Low 25-Hydroxyvitamin D Level Is Associated with Peripheral Arterial in Type 2 Diabetes Patients.”>
Low 25-Hydroxyvitamin D Level Is Associated with Peripheral Arterial in Type 2 Diabetes Patients.

February 2016

BACKGROUND AND AIMS: Patients with type 2 diabetes have an increased risk of atherosclerosis and vascular . Vitamin D deficiency is associated with vascular and is prevalent in diabetes patients. We undertook this study to determine the association between 25-hydroxyvitamin D (25[OH]D) levels and prevalence of peripheral arterial (PAD) in type 2 diabetes patients.
METHODS:
A total of 1028 type 2 diabetes patients were recruited at Nanjing Medical University Affiliated Nanjing Hospital from November 2011-October 2013. PAD was defined as an ankle-brachial index (ABI)

/ onclick=”MoreLine(‘8976’, ‘Low 25-Hydroxyvitamin D Level Is Associated with Peripheral Arterial in Type 2 Diabetes Patients.’)”>
…more

/ title=”Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.”>
Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.

January 2011

OBJECTIVE:
To evaluate the association of chocolate consumption with the risk of developing cardiometabolic disorders.
DESIGN:
Systematic review and meta-analysis of randomised controlled trials and observational studies. DATA SOURCES: Medline, Embase, Cochrane Library, PubMed, CINAHL, IPA, Web of Science, Scopus, Pascal, reference lists of relevant studies to October 2010, and email contact with authors. STUDY SELECTION: Randomised trials and cohort, case-control, and cross sectional studies carried out in human adults, in which the association between chocolate consumption and the risk of outcomes related to cardiometabolic disorders were reported. DATA EXTRACTION: Data were extracted by two independent investigators, and a consensus was reached with the involvement of a third. The primary outcome was cardiometabolic disorders, including cardiovascular (coronary heart and stroke), diabetes, and metabolic syndrome. A meta-analysis assessed the risk of developing cardiometabolic disorders by comparing the highest and lowest level of chocolate consumption.
Results:
From 4576 references seven studies met the inclusion criteria (including 114?009 participants). None of the studies was a randomised trial, six were cohort studies, and one a cross sectional study. Large variation was observed between these seven studies for measurement of chocolate consumption, methods, and outcomes evaluated. Five of the seven studies reported a beneficial association between higher levels of chocolate consumption and the risk of cardiometabolic disorders. The highest levels of chocolate consumption were associated with a 37% reduction in cardiovascular (relative risk 0.63 (95% confidence interval 0.44 to 0.90)) and a 29% reduction in stroke compared with the lowest levels. CONCLUSIONS: Based on observational evidence, levels of chocolate consumption seem to be associated with a substantial reduction in the risk of cardiometabolic disorders. Further experimental studies are required to confirm a potentially beneficial effect of chocolate consumption.

/ onclick=”MoreLine(‘8500’, ‘Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis.’)”>
…more

Have a Question?